HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome
Mahdi Golkaram(Illumina (United States)), Li Liu(Shihezi University), Nafeesa Khan(Illumina (United States)), João Malaquias(University of Aveiro), Traci Pawlowski(Illumina (United States)), Michael Salmans(Illumina (United States)), Paula Borralho(Instituto de Medicina Molecular João Lobo Antunes), Sandra Casimiro(University of Lisbon), Jim Godsey(Illumina (United States)), Shile Zhang(Guardant (United States)), Luís Costa(University of Lisbon), Marta Martins(Instituto de Medicina Molecular João Lobo Antunes), Daniela Macedo(Centro Hospitalar Lisboa Norte), Joyee Yao(Illumina (United States)), Shannon Kaplan(Illumina (United States)), André Mansinho(Hospital de Santa Maria), Aaron Wise(Illumina (United States)), Pedro Marques da Costa(University of Lisbon), Ana Lúcia Costa(Centro Hospitalar Lisboa Norte), Cassandra C. Garbutt(Illumina (United States)), Cecília Alvim(Centro Hospitalar Lisboa Norte), Catarina Abreu(Hospital Garcia de Orta), Fernando Aldeia(Centro Hospitalar Lisboa Norte), Afonso Fernandes(Hospital de São João), Alex So(Illumina (United States)), Cristina Ferreira(Centro Hospitalar Lisboa Norte), Pedro Filipe(Centro Hospitalar Lisboa Norte), Raakhee Vijayaraghavan(Illumina (United States))
Cited by 37
Related Papers
Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis
|The Lancet|2014|3.2k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain
|Science|2016|1.1k
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
|Cancer Research|2009|490